1.
Clin Infect Dis
; 61(8): 1304-6, 2015 Oct 15.
Article
in English
| MEDLINE
| ID: mdl-26082511
ABSTRACT
Treatment of hepatitis C virus with potent, interferon-free, direct-acting antiviral regimens with no activity against hepatitis B virus (HBV) may increase the risk for HBV reactivation in coinfected patients. We present 2 cases of HBV reactivation during treatment with an all-oral regimen of simeprevir and sofosbuvir and discuss strategies to prevent HBV flare.
